Thromboxane A2 Antagonist : Discovery of Seratrodast
Bibliographic Information
- Other Title
-
- トロンボキサンA2受容体拮抗薬 : セラトロダストの創製研究
- トロンボキサン A2 ジュヨウタイ キッコウヤク セラトロダスト ノ ソウセイ ケンキュウ
Search this article
Abstract
We were interested in RCS (rabbit aorta contracting substance) and SRS-A(slow reacting substance of anaphylaxis) and their involvement in human bronchial asthma. When we started our anti-asthmatic drug research in the 1970's. We synthesized a lot of chemical compounds and eventually discovered that AA-861 inhibited the generation of SRS-A from the lung tissue of actively sensitized guinea pigs. AA-861 was found to be a potent 5-lipoxygenase inhibitor. This compound reduced experimental allergic asthma in guinea pigs, but it is easily metabolized in the body. More recently, we found a novel compound, AA-2414 (seratrodast), which is not metabolized in the body. AA-2414 proved to be not a 5-lipoxygenase inhibitor, but a thromboxane A2 (TXA2) receptor antagonist. Seratrodast is the first receptor antagonist that is being developed as an anti-asthmatic drug. Seratrodast inhibits both immediate-, late asthmatic responses in guinea pigs, and also reduces airway hyperresponsiveness in dogs. The anti-asthmatic action of seratrodast in animal models indicates that the drug should be of use in the treatment of human asthmatics. In clinical studies, seratrodast showed a marked effect to improve clinical parameters in bronchial asthma. It is also reported that seratrodast is free from harmful aftereffects. Clinical trials are under way in the US.
Journal
-
- YAKUGAKU ZASSHI
-
YAKUGAKU ZASSHI 119 (5), 377-390, 1999
The Pharmaceutical Society of Japan
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282681130439424
-
- NII Article ID
- 110003648745
-
- NII Book ID
- AN00284903
-
- ISSN
- 13475231
- 00316903
-
- NDL BIB ID
- 4711910
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed